JP7623006B2 - 特異的結合剤により認識されるエピトープタグ - Google Patents

特異的結合剤により認識されるエピトープタグ Download PDF

Info

Publication number
JP7623006B2
JP7623006B2 JP2021537505A JP2021537505A JP7623006B2 JP 7623006 B2 JP7623006 B2 JP 7623006B2 JP 2021537505 A JP2021537505 A JP 2021537505A JP 2021537505 A JP2021537505 A JP 2021537505A JP 7623006 B2 JP7623006 B2 JP 7623006B2
Authority
JP
Japan
Prior art keywords
antibody
alfa
sequence
seq
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021537505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500076A (ja
JPWO2020053239A5 (enExample
Inventor
シュテッフェン フレイ
ハンスイェルク ゲッケ
ダビラ ルイス フェリペ オパソ
ポール エリク グスタフ ステンマルク
カランサ マーケル マルティネス
Original Assignee
ナノタグ バイオテクノロジーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナノタグ バイオテクノロジーズ ゲーエムベーハー filed Critical ナノタグ バイオテクノロジーズ ゲーエムベーハー
Publication of JP2022500076A publication Critical patent/JP2022500076A/ja
Publication of JPWO2020053239A5 publication Critical patent/JPWO2020053239A5/ja
Application granted granted Critical
Publication of JP7623006B2 publication Critical patent/JP7623006B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021537505A 2018-09-11 2019-09-11 特異的結合剤により認識されるエピトープタグ Active JP7623006B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18193663.4 2018-09-11
EP18193663 2018-09-11
EP19160485.9 2019-03-04
EP19160485 2019-03-04
PCT/EP2019/074153 WO2020053239A1 (en) 2018-09-11 2019-09-11 Epitope tags recognized by specific binders

Publications (3)

Publication Number Publication Date
JP2022500076A JP2022500076A (ja) 2022-01-04
JPWO2020053239A5 JPWO2020053239A5 (enExample) 2022-09-16
JP7623006B2 true JP7623006B2 (ja) 2025-01-28

Family

ID=68138006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537505A Active JP7623006B2 (ja) 2018-09-11 2019-09-11 特異的結合剤により認識されるエピトープタグ

Country Status (5)

Country Link
US (1) US12365705B2 (enExample)
EP (1) EP3849996A1 (enExample)
JP (1) JP7623006B2 (enExample)
CN (1) CN113195516B (enExample)
WO (1) WO2020053239A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250154202A1 (en) * 2022-02-02 2025-05-15 BioNTech SE Cyclic epitope tags
EP4472672A1 (en) * 2022-02-02 2024-12-11 BioNTech SE Agents and methods for targeted delivery to cells
WO2023148277A1 (en) * 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery of nucleic acids to cells
US20250136717A1 (en) 2022-05-16 2025-05-01 Byondis B.V. Novel masked antibodies
CN117802045A (zh) 2022-09-30 2024-04-02 北京恩康医药有限公司 一种工程化细胞外囊泡的构建及其应用
JPWO2024172152A1 (enExample) * 2023-02-17 2024-08-22
WO2025021277A1 (en) * 2023-07-21 2025-01-30 BioNTech SE Agents and methods for targeted delivery of cytokines to immune cells
EP4520768A1 (en) 2023-09-06 2025-03-12 BioNTech SE Vhh-ch3 fusion proteins
WO2025078418A1 (en) 2023-10-10 2025-04-17 Nano Tag Biotechnologies Gmbh Humanized single-domain antibodies binding to epitope tags
TW202535921A (zh) 2023-10-11 2025-09-16 德商拜恩迪克公司 用於靶向遞送免疫效應子細胞之試劑及方法
WO2025219955A1 (en) * 2024-04-17 2025-10-23 BioNTech SE Soluble tcrs and methods of use thereof
CN120923600A (zh) * 2024-05-09 2025-11-11 福建医科大学 一种超稳定红色荧光蛋白
CN118909142A (zh) * 2024-08-07 2024-11-08 北京爱思益普生物科技股份有限公司 Irak4蛋白的制备方法及其所采用的融合蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330523D1 (de) * 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
US20040014955A1 (en) * 2001-12-17 2004-01-22 Carlos Zamudio Identification of essential genes of cryptococcus neoformans and methods of use
AU2003286002B2 (en) * 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AR067584A1 (es) * 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
US7678883B2 (en) * 2007-07-25 2010-03-16 E.I. Du Pont De Nemours And Company Solubility tags for the expression and purification of bioactive peptides
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
CA2964119C (en) * 2014-11-03 2022-10-18 Merck Patent Gmbh Soluble intein fusion proteins and methods for purifying biomolecules
EP3168306A1 (en) 2015-11-16 2017-05-17 ChromoTek GmbH Epitope tag and method for detection and/or purification of tagged polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Science，2005年，Vol.307/No.5713，P.1321-1324

Also Published As

Publication number Publication date
CN113195516B (zh) 2025-07-15
WO2020053239A1 (en) 2020-03-19
JP2022500076A (ja) 2022-01-04
CN113195516A (zh) 2021-07-30
EP3849996A1 (en) 2021-07-21
US12365705B2 (en) 2025-07-22
US20220048947A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
JP7623006B2 (ja) 特異的結合剤により認識されるエピトープタグ
CN103649119B (zh) 特异性结合胰岛素样生长因子1的抗体
US11098081B2 (en) Epitope tag and method for detection and/or purification of tagged polypeptides
JP2024147571A (ja) 可溶性ｂｃｍａに対する抗体
US20240027467A1 (en) Nanobody Exchange Chromatography
US20250263449A1 (en) Multivalent proteins and screening methods
US11008365B2 (en) Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure
WO2023077172A2 (en) Novel anti-lilrb2 antibodies and derivative products
JP6245688B2 (ja) ＩｇＹ特異的結合ペプチド及びそれによるＩｇＹの精製法
WO2025078418A1 (en) Humanized single-domain antibodies binding to epitope tags
JP2024519333A (ja) Ｍｅｒｔｋペプチドおよびその使用
HK1191348B (en) An antibody specifically binding to insulin-like growth factor-1
HK1191348A (en) An antibody specifically binding to insulin-like growth factor-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230828

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250108

R150 Certificate of patent or registration of utility model

Ref document number: 7623006

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150